Recently, I provided opening remarks at an event that brought together various stakeholders to discuss opportunities and challenges presented by the introduction of biosimilar drugs to cancer systems across Canada. The issue is both important and timely, as we expect the first therapeutic biosimilar to be marketed for oncology in this country in 2019.
One of the most memorable letters I have ever received as president and CEO of CCO was from the wife of a man with stage 4 cancer. The question underlying her heartfelt letter was Why? Why did her husband get cancer even though he had (as she put it) “done everything right”?